Phase II double-blind placebo-controlled randomized study of armodafinil for brain radiation-induced fatigue

Neuro-Oncology

Volumn 17, Issue 10, 2015, Pages 1393-1401

  Page, Brandi R ^a   Shaw, Edward G ^a   Lu, Lingyi ^a   Bryant, David ^b   Grisell, David ^c   Lesser, Glenn J ^a   Monitto, Drew C ^a,d   Naughton, Michelle J ^g   Rapp, Stephen R ^a   Savona, Steven R ^e   Shah, Sunjay ^f   Case, Doug ^a   Chan, Michael D ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b Via Christi Cancer Center ^*  (United States)

^c GREENVILLE HOSPITAL SYSTEM   (United States)

^d Gibbs Cancer Center and Research Institute   (United States)

^e DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^f CHRISTIANA CARE HEALTH SYSTEM   (United States)

^g OHIO STATE UNIVERSITY   (United States)

Author keywords

armodafinil; cognitive function; fatigue; primary brain tumors; radiotherapy

Indexed keywords

ARMODAFINIL; PLACEBO; BENZHYDRYL DERIVATIVE; WAKEFULNESS PROMOTING AGENT;

ADULT; ANXIETY DISORDER; ARTHRALGIA; ARTICLE; ASSESSMENT OF HUMANS; BRAIN RADIATION; BRAIN TUMOR; BRIEF FATIGUE INVENTORY; COGNITION; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; EPWORTH SLEEPINESS SCALE; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT; FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY FATIGUE; HEADACHE; HUMAN; INSOMNIA; MALE; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SOMNOLENCE; SORE THROAT; THORAX PAIN; UPPER RESPIRATORY TRACT INFECTION; XEROSTOMIA; ADVERSE EFFECTS; AGED; BRAIN NEOPLASMS; CLINICAL TRIAL; COMPLICATION; GLIOBLASTOMA; MENINGIOMA; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; TREATMENT OUTCOME;

ADULT; AGED; BENZHYDRYL COMPOUNDS; BRAIN NEOPLASMS; DOUBLE-BLIND METHOD; FATIGUE; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MENINGIOMA; MIDDLE AGED; QUALITY OF LIFE; RADIOTHERAPY; TREATMENT OUTCOME; WAKEFULNESS-PROMOTING AGENTS;

EID: 84943392559     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nov084     Document Type: Article

References (36)

1. Greene-Schloesser D, Robbins ME, Peiffer AM, et al. Radiationinduced brain injury: A review. Front Oncol. 2012;2:73.
2. Soffietti R, Kocher M, Abacioglu UM, et al. A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. J Clin Oncol. 2013;31(1):65-72.
3. Attia A, Page BR, Lesser GJ, et al. Treatment of radiation-induced cognitive decline. Curr Treat Options Oncol. 2014;15:539-550.
4. Kohli S, Fisher SG, Tra Y, et al. The effect of modafinil on cognitive function in breast cancer survivors. Cancer. 2009;115(12): 2605-2616.
5. Weitzner MA, Meyers CA, Valentine AD. Methylphenidate in the treatment of neurobehavioral slowing associated with cancer and cancer treatment. J Neuropsychiatry Clin Neurosci. 1995; 7(3):347-350.
6. Meyers CA, Weitzner MA, Valentine AD, et al. Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol. 1998;16(7):2522-2527.
7. Masand PS, Tesar GE. Use of stimulants in the medically ill. Psychiatr Clin North Am. 1996;19(3):515-547.
8. Webster K, Odom L, Peterman A, et al. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Validation of version 4 of the core questionnaire. Qual Life Res. 1999;8(7):604.
9. Butler JM Jr., Case LD, Atkins J, et al. A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy. Int J Radiat Oncol Biol Phys. 2007;69(5): 1496-1501.
10. Broughton RJ, Fleming JA, George CF, et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology. 1997;49(2):444-451.
11. Armodafinil investigator's brochure. 5 ed. Frazer, PA: Cephalon, Inc; 2008.
12. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. US Modafinil in Narcolepsy Multicenter Study Group. Ann Neurol. 1998;43(1):88-97.
13. Jean-Pierre P, Morrow GR, Roscoe JA, et al. A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study. Cancer. 2010;116(14):3513-3520.
14. Kaleita TA, Wellisch DK, Graham CA, et al. Pilot study of modafinil for treatment of neurobehavioral dysfunction and fatigue in adult patients with brain tumors. J Clin Oncol. 2006;24:1503.
15. Boele FW, Douw L, de Groot M, et al. The effect of modafinil on fatigue, cognitive functioning, and mood in primary brain tumor patients: a multicenter randomized controlled trial. Neuro Oncol. 2013;15(10):1420-1428.
16. Gehring K, Patwardhan SY, Collins R, et al. A randomized trial on the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary brain tumor. J Neurooncol. 2012;107(1):165-174.
17. Dinges DF, Arora S, Darwish M, et al. Pharmacodynamic effects on alertness of single doses of armodafinil in healthy subjects during a nocturnal period of acute sleep loss. Curr Med Res Opin. 2006; 22(1):159-167.
18. Roth T, White D, Schmidt-NowaraW, et al. Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults. Clin Ther. 2006;28(5):689-706.
19. Harsh JR, Hayduk R, Rosenberg R, et al. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin. 2006;22(4): 761-774.
20. Cella D, Eton DT, Lai JS, et al. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage. 2002;24(6):547-561.
21. Yellen SB, Cella DF, Webster K, et al. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage. 1997;13(2):63-74.
22. Radloff LS. The CES-D Scale: A Self-Report Depression Scale for Research in the General Population. Appl Psychol Meas. 1977; 1(3):385-401.
23. Weitzner MA, Meyers CA, Gelke CK, et al. The Functional Assessment of Cancer Therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer. 1995;75(5): 1151-1161.
24. Benton A. Development of a multilingual aphasia battery: Progress and problems. J Neurol Sci. 1969;9(1):39-48.
25. Benedict RH, Schretlen D, Groninger L, et al. Hopkins Verbal Learning Test, Revised: Normative data and analysis of inter-form and test-retest reliability. Clin Neuropsychol. 1998; 12(1):43-55.
26. Slotman BJ, Mauer ME, Bottomley A, et al. Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms: results of an international Phase III randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer Groups. J Clin Oncol. 2009;27(1):78-84.
27. Reitan RM. Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills. 1958;8(3):271-276.
28. Mendoza TR, Wang XS, Cleeland CS, et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer. 1999;85(5):1186-1196.
29. Johns MW. Reliability and factor analysis of the Epworth Sleepiness Scale. Sleep. 1992;15(4):376-381.
30. Shaw EG, Rosdhal R, D'Agostino RB Jr., et al. Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. J Clin Oncol. 2006;24(9): 1415-1420.
31. Fitzmaurice G, Laird N,Ware J. Applied Longitudinal Analysis. Vol 2. Hoboken, NJ: John Wiley & Sons; 2011.
32. Brown PD, Ballman KV, Rummans TA, et al. Prospective study of quality of life in adults with newly diagnosed high-grade gliomas. J Neurooncol. 2006;76(3):283-291.
33. Osoba D, Brada M, Prados MD, et al. Effect of disease burden on health-related quality of life in patients with malignant gliomas. Neuro Oncol. 2000;2(4):221-228.
34. Lee EQ, Muzikansky A, Kesari S, et al. randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy [abstract]. J Clin Oncol. 2014;32(suppl 5):2004.
35. Peiffer AM, Leyrer CM, Greene-Schloesser DM, et al. Neuroanatomical target theory as a predictive model for radiation-induced cognitive decline. Neurology. 2013;80(8): 747-753.
36. Maquilan G, Grover S, Alonso-Basanta M, et al. Acute toxicity profile of patients with low-grade gliomas and meningiomas receiving proton therapy. Am J Clin Oncol. 2014;37(5):438-443.